Prevalence and Determinants of Hearing Loss in Multidrug-Resistant Tuberculosis Patients: A Prospective Observational Cohort Study in Kinshasa, Democratic Republic of the Congo.
DOI:
https://doi.org/10.47941/ijhmnp.3238Keywords:
Multidrug, Resistant Tuberculosis, Determinants, Hearing LossAbstract
Purpose. The occurrence of the hearing loss (HL) is a challenge during the treatment of multidrug-resistant tuberculosis (MDR-TB). Aminoglycoside-based regimen, to a lesser extent based on bedaquiline (BDQ), induce ototoxic HL. Identifying associated risk factors is crucial in a resource-limited setting. This study assessed the determinants of the HL in patients with MDR-TB. Methodology. This prospective observational multicenter cohort study included patients with MDR-TB. It was performed in Kinshasa (Democratic Republic of the Congo) between February 15, 2020 and February 14, 2021. Sociodemographic, clinical, biological, therapeutic, and audiometric data were exported and analyzed using Stata 17 and MedCalc. The fixed-effect linear regression panel model was used to assess the degree of the HL over time according to the following covariates: therapeutic regimen (aminoglycosides, bedaquiline, or alternate), chronic kidney disease (CKD), age at inclusion, body mass index, serum albumin level, HIV status, alcohol intake, hypertension, and hemoglobin level. The Hausman test was used to select between fixed- and random-effect estimators. The threshold for statistical significance was set at p < 0.05.Findings. Of the 337 patients included, 236 (70%) received an aminoglycoside-based regimen, 61 (18%) received a bedaquiline-based regimen, and 40 (12%) received an aminoglycosides (AG) relayed by BDQ. The frequency of the HL increased from 62% to 96.3% within six months for all therapeutic regimens. The HL worsened, with moderate (72.4%) and profound (16%) deafness being predominant. An exposure to the treatment for more than one month (β coeff: 27.695, Se: 0.793, p< 0.001), aminoglycoside-based regimen, age ≥ 40 years (β coeff: 6.102, Se: 1.779, p< 0.001), hypoalbuminemia (β coeff: 5.610, Se: 1.682, p= 0.001), and the estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 (β coeff: 6.730, Se: 2.70, p= 0.013) were the independent risk factors associated with the HL in MDR-TB patients.
Unique contributor to theory, policy and practice: The hearing loss is more prevalent and worsens during the treatment of the patients with MDR-TB. A systematic audiometric evaluation and monitoring plan are needed for the management of these patients. It should focus on the elderly patients, and those who have an exposure for more than one month, an aminoglycoside-based regimen, a hypoalbuminemia, and have an impaired kidney function. However, further prospective interventional cohort studies are required to assess the incidence of the HL during the MDR-TB treatment.
Downloads
References
1. Global tuberculosis report 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO.
https://iris.who.int/bitstream/handle/10665/379339/9789240101531eng.pdf?sequence=1
2. Framework for implementing the “End TB Strategy” in the African Region 2016-2020. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.
https://iris.who.int/bitstream/handle/10665/259636/TBstrat-eng.pdf?sequence=1
3. Kashongwe, I., Mbulula, L., Mawete, F., Anshambi, N., Maingowa, N., Kaswa, M., et al. Implementing a Short Regimen for Multidrug-Resistant Tuberculosis in Kinshasa, Democratic Republic of Congo: A Cohort Study 2014-2017. J. Tuberc. Res. 2020; 8, 111-126. doi: 10.4236/jtr.2020.83010.
4. V. Poka-Mayap, D. Balkissou Adamou, E.W. Pefura-Yone, C. Kuaban, Déterminants de l’ototoxicité induite par les aminosides au cours du traitement de la tuberculose multirésistante au Cameroun. Rev Mal Respir. 2017;,Volume 34, Supplement, Pages A218-A219, ISSN 0761-8425, https://doi.org/10.1016/j.rmr.2016.10.521.
5. World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment. World Health Organization (2020). https://www.who.int/publications/i/item/9789240107243
6. Kashongwe, I.M., Anshambi, N., Maingowa, N., Aloni, M., Kaswa, M., Ntumba Kayembe, J.M., et al. Use of Bedaquiline as Replacement for Aminoglycosides in the Shorter Regimen for Multidrug-Resistant Tuberculosis Patients with Hearing Loss: A Report of 39 Cases in Kinshasa, Democratic Republic of the Congo. Journal of Pulmonary & Respiratory Medicine. 2020; 10, 1-6.
7. World Health Organization. Deafness and hearing loss (2025). https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss
8. Chadha S, Kamenov K, Cieza A. The World report on hearing, 2021. Bull World Health Organ. 2021; 99(4):242-242A. doi: 10.2471/BLT.21.285643
9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252
10. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120(16):1640-5.
11. World health Organization Obesity and overweight (2025). https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
12. Babor T.F, Higgins-Biddle J.C, Saunders J.B.,Monteiro M.G. AUDIT.-The Alcohol Use Disorders Identification Test : Guidelines for Use in Primary Care (Second Edidtion) (2001). https://www.who.int/publications/i/item/WHO-MSD-MSB-01.6a
13. Orth SR, Stockmann A, Conradt C, Ritz E, Ferro M, Kreusser W, et al. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int 1998, 54(3): 926 -31.
14. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity (2011). https://www.who.int/publications/i/item/WHO-NMH-NHD-MNM-11.1
15. Oster HS, Dolev Y, Kehat O, Weis-Meilik A, Mittelman M. Serum Hypoalbuminemia Is a Long-Term Prognostic Marker in Medical Hospitalized Patients, Irrespective of the Underlying Disease. J Clin Med. 2022; 11(5):1207. doi: 10.3390/jcm11051207. PMID: 35268297; PMCID: PMC8911288
16. KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney international supplements. 2013, 3(1): 1 – 160.
17. Mpwate AM, Matanda NR, Mupepe MD, Mafuta ME. Surdités neurosensorielles: à propos de 97 observations aux Cliniques Universitaires de Kinshasa. Ann. Afr. Med. 2012; 6(1): 1232-1241.
18. Modongo C, Sobota RS, Kesenogile B, Ncube R, Sirugo G, Williams SM, et al. Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss. BMC Infect Dis. 2014; 14:542.
19. Hong H, Dowdy DW, Dooley KE, Francis HW, Budhathoki C, Han HR et al. Aminoglycoside-induced Hearing Loss Among Patients Being Treated for Drug-resistant Tuberculosis in South Africa: A Prediction Model. Clin Infect Dis. 2020; 14; 70(5):917-924. doi: 10.1093/cid/ciz289.
20. Sogebi OA, Adefuye BO, Adebola SO, Oladeji SM, Adedeji TO. Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy. Auris Nasus Larynx. 2017; 44(4):404-410. doi: 10.1016/j.anl.2016.10.005.
21. Henry JA, Roberts LE, Caspary DM, Theodoroff SM, Salvi RJ. Underlying mechanisms of tinnitus: review and clinical implications. J Am Acad Audiol. 2014; 25(1):5-22; quiz 126. doi: 10.3766/jaaa.25.1.2
22. Fassad MR, Desouky LM, Asal S, Abdalla EM. Screening for the mitochondrial A1555G mutation among Egyptian patients with non-syndromic, sensorineural hearing loss. Int J Mol Epidemiol Genet. 2014; 5(4):200-4. PMID: 25755848; PMCID: PMC4348701.
23. Sturdy A, Goodman A, José RJ, Loyse A, O'Donoghue M, Kon OM, et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother. 2011; 66(8):1815-20. doi: 10.1093/jac/dkr221
24. Duggal P, Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear Nose Throat Disord. 2007; 7:5. doi: 10.1186/1472-6815-7-5
25. Soh AZ, Chee CBE, Wang YT, Yuan JM, Koh WP. Alcohol drinking and cigarette smoking in relation to risk of active tuberculosis: prospective cohort study. BMJ Open Respir Res. 2017; 4(1):e000247. doi: 10.1136/bmjresp-2017-000247.
26. Simou E, Britton J, Leonardi-Bee J. Alcohol consumption and risk of tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2018; 22(11):1277-1285. doi: 10.5588/ijtld.18.0092.
27. Cormier M, Schwartzman K, N'Diaye DS, Boone CE, Dos Santos AM, Gaspar J et al. Proximate determinants of tuberculosis in Indigenous peoples worldwide: a systematic review. Lancet Glob Health. 2019; 7(1):e68-e80. doi: 10.1016/S2214-109X(18)30435-2.
28. Silva DR, Muñoz-Torrico M, Duarte R, Galvão T, Bonini EH, Arbex FF et al. Risk factors for tuberculosis: diabetes, smoking, alcohol use, and the use of other drugs. J Bras Pneumol. 2018; 44(2):145-152. doi: 10.1590/s1806-37562017000000443.
29. Lampalo M, Jukić I, Bingulac-Popović J, Stanić HS, Barišić B, Popović-Grle S. The role of cigarette smoking and alcohol consumption in pulmonary tuberculosis development and recurrence. Acta Clin Croat 2019; 58(4):590-594.
30. Wessels J, Walsh CM, Nel M. Smoking habits and alcohol use of patients with tuberculosis at Standerton Tuberculosis Specialised Hospital, Mpumalanga, South Africa. Health SA. 2019; 24:1146. doi: 10.4102/hsag.v24i0.1146.
31. Patra J, Jha P, Rehm J, Suraweera W. Tobacco smoking, alcohol drinking, diabetes, low body mass index and the risk of self-reported symptoms of active tuberculosis: individual participant data (IPD) meta-analyses of 72,684 individuals in 14 high tuberculosis burden countries. PLoS One. 2014; 9(5):e96433. doi: 10.1371/journal.pone.0096433.
32. Torre P 3rd, Hoffman HJ, Springer G, Cox C, Young MA, Margolick JB, et al. Hearing loss among HIV-seropositive and HIV-seronegative men and women. JAMA Otolaryngol Head Neck Surg. 2015; 141(3):202-10. doi: 10.1001/jamaoto.2014.3302. PMID: 25541676; PMCID: PMC4369193.
33. Al-Malky G, Dawson SJ, Sirimanna T, Bagkeris E, Suri R. High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis. J Cyst Fibros. 2015; 14(2):248-54. doi: 10.1016/j.jcf.2014.07.009
34. Ahmed RM, Hannigan IP, MacDougall HG, Chan RC, Halmagyi GM. Gentamicin ototoxicity: a 23-year selected case series of 103 patients. Med J Aust. 2012; 196(11):701-4. doi: 10.5694/mja11.10850.
35. Van Altena R, Dijkstra JA, van der Meer ME, Borjas Howard JF, Kosterink JG, van Soolingen D, et al. Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother. 2017; 61(3):e01400-16. doi: 10.1128/AAC.01400-16
36. Pai MP, Nafziger AN, Bertino JS Jr. Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother. 2011; 55(9):4006-11. doi: 10.1128/AAC.00174-11.
37. Emmett SD, Schmitz J, Karna SL, Khatry SK, Wu L, LeClerq SC, et al. Early childhood undernutrition increases risk of hearing loss in young adulthood in rural Nepal. Am J Clin Nutr. 2018; 107(2):268-277. doi: 10.1093/ajcn/nqx022
38. Guthrie OW. Aminoglycoside induced ototoxicity. Toxicology. 2008; 249(2-3):91-6. doi: 10.1016/j.tox.2008.04.015.
39. Lesniak W, Pecoraro VL, Schacht J. Ternary complexes of gentamicin with iron and lipid catalyze formation of reactive oxygen species. Chem Res Toxicol. 2005; 18(2):357-64. doi: 10.1021/tx0496946.
40. Minhas RS, Iyengar DA, Thakur JS, Azad RK. Effect of HIV and Antiretroviral Treatment on Auditory Functions. Int Arch Otorhinolaryngol. 2018; 22(4):378-381. doi: 10.1055/s-0038-1639594. Epub 2018 Mar 29. PMID: 30357077; PMCID: PMC6197983.
41. Harris T, Bardien S, Schaaf HS, Petersen L, De Jong G, Fagan JJ. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. S Afr Med J. 2012; 102(6 Pt 2):363-6. doi: 10.7196/samj.4964.
42. De Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis. 2002; 6(7):622-7. PMID: 12102302.
43. Igumnova V, Veidemane L, Vīksna A, Capligina V, Zole E, Ranka R. The prevalence of mitochondrial mutations associated with aminoglycoside-induced deafness in ethnic Latvian population: the appraisal of the evidence. J Hum Genet. 2019 ; 64(3):199-206. doi: 10.1038/s10038-018-0544-6.
44. Ealy M, Lynch KA, Meyer NC, Smith RJ. The prevalence of mitochondrial mutations associated with aminoglycoside-induced sensorineural hearing loss in an NICU population. Laryngoscope. 2011; 121(6):1184-6. doi: 10.1002/lary.21778.
45. Zeidan, H.M., Abd El Hady, H., Omara, A., Meguid N.A and Taha MS. Analysis of mitochondrial 12S rRNA A1555G genetic mutation in group of Egyptian children with non-syndromic hearing loss: cross-sectional observational study. Egypt J Otolaryngol 41, 88 (2025). https://doi.org/10.1186/s43163-025-00839-x
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Mireille Avilaw Mpwate, Gauthier K. Mesia, Eddy Mampuya Mbambu, Gabriel Mabuaka Lema, Christian Nzanza Matanda, Dominique Mayuku Mupepe, Luc Losenga Lukasu, Pierre Zalagile Akilimali, Innocent Murhula Kashongwe, Zacharie Munogolo Kashongwe, Jean Marie Ntumba Kayembe, Richard Nzanza Matanda
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
